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Background: The Plasmodium falciparum protein RH5 is an adhesin molecule essential for parasite invasion of
erythrocytes. Recent studies show that anti-PfRH5 sera have potent invasion-inhibiting activities, supporting the idea
that the PfRH5 antigen could form the basis of a vaccine. Therefore, epitopes recognized by neutralizing anti-PfRH5
antibodies could themselves be effective vaccine immunogens if presented in a sufficiently immunogenic fashion.
However, the exact regions within PfRH5 that are targets of this invasion-inhibitory activity have yet to be identified.
Methods: A battery of anti-RH5 monoclonal antibodies (mAbs) were produced and screened for their potency by
inhibition of invasion assays in vitro. Using an anti-RH5 mAb that completely inhibited invasion as the selecting
mAb, affinity-selection using random sequence peptide libraries displayed on virus-like particles of bacteriophage
MS2 (MS2 VLPs) was performed. VLPs were sequenced to identify the specific peptide epitopes they encoded and
used to raise specific antisera that was in turn tested for inhibition of invasion.
Results: Three anti-RH5 monoclonals (0.1 mg/mL) were able to inhibit invasion in vitro by >95%. Affinity-selection with
one of these mAbs yielded a VLP which yielded a peptide whose sequence is identical to a portion of PfRH5 itself. The
VLP displaying the peptide binds strongly to the antibody, and in immunized animals elicits an anti-PfRH5 antibody
response. The resulting antisera against the specific VLP inhibit parasite invasion of erythrocytes more than 90% in vitro.
Conclusions: Here, data is presented from an anti-PfRH5 mAb that completely inhibits erythrocyte invasion by parasites
in vitro, one of the few anti-malarial monoclonal antibodies reported to date that completely inhibits invasion with such
potency, adding to other studies that highlight the potential of PfRH5 as a vaccine antigen. The specific neutralization
sensitive epitope within RH5 has been identified, and antibodies against this epitope also elicit high anti-invasion activity,
suggesting this epitope could form the basis of an effective vaccine against malaria.Background
Clinical symptoms of malaria are due to the blood-stage
of infection in which merozoites invade erythrocytes, and
multiply until the cell bursts, thereby liberating progeny
merozoites that in turn invade new erythrocytes [1]. The
parasite invades erythrocytes via multiple pathways. In the
case of Plasmodium falciparum the two principal routes
are the sialic acid (SA)-dependent and SA-independent
pathways [2]. The glycophorin (GP) receptors are the
main sialylated proteins on the RBC surface, and the
parasite adhesins that bind GPs govern the SA-
dependent pathway. They include members of the* Correspondence: CLobo@nybloodcenter.org
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unless otherwise stated.erythrocyte binding ligand (EBL) family, such as EBA-175
[1,3-9], and PfRH1 [10]. Antigens identified as utilizing the
SA-independent pathway are mainly, but not exclusively,
comprised of the reticulocyte binding protein-like homo-
logues (RH), RH2a, RH2b, RH4 and RH5 [9,11-13]. The
RBC receptors bound by RH2a and RH2b have not yet
been fully identified; RH4 binds to complement receptor
(CR) 1 [14], and RH5 binds to basigin [15].
PfRH5 appears to be essential for erythrocyte invasion.
Not only is the PfRH5-basigin interaction required for
erythrocyte invasion by all tested strains of P. falciparum
[15], but repeated unsuccessful attempts to delete the
PfRH5 gene suggest the protein is needed for viability
[12,16,17]. Whole genome sequencing of almost 300
clinical P. falciparum isolates identified only five non-
synonymous PfRH5 SNPs [18], revealing that the protein. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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others have shown potent inhibition of invasion using
antibodies raised against recombinant PfRH5 protein
[19-21]. Recently, naturally acquired anti-PfRH5 anti-
bodies from the sera of malaria patients were also shown
to be inhibitory in vitro and correlate with protection from
malaria [22,23]. All this points to PfRH5’s promise as a
vaccine antigen, and to the possibility that epitopes rec-
ognized by neutralizing antibodies could themselves be
effective vaccine immunogens if presented in a sufficiently
immunogenic fashion. However, until recently [24] no
study has identified the actual regions on PfRH5 that are
either responsible for red cell binding or are targets of this
invasion-inhibitory activity.
In this study, a monoclonal antibody that completely
prevents red cell invasion by the parasite in vitro was
identified, as well as two other mAbs that inhibit invasion
by greater than 95%, of any anti-malarial monoclonal
antibodies that are able to so potently inhibit parasite
invasion. Using a bacteriophage virus-like particle (VLP)
based peptide display platform, the specific neutralization-
sensitive epitope targeted by one of these monoclonal
antibodies was identified. Vaccination with VLPs display-
ing this epitope elicits antibodies that, in turn, potently
inhibit erythrocyte invasion by P. falciparum.
Methods
Animal work and ethics statement
Animal protocols in this study were reviewed and approved
by the A&G (protocol #AG-01) and University of New
Mexico (protocol #12-100865-HSC) Institutional Animal
Care and Use Committees (IACUC) to ensure they met
with strict accordance to the recommendations of the
Guide for the Care and Use of Laboratory Animals of the
NIH. Isoflurane was used to sedate the mice for immuni-
zations, and all efforts were made to minimize suffering at
all times.
Preparation of mouse hybridomas and monoclonal
antibodies
Monoclonal antibodies were generated by Precision Anti-
body (a wholly owned service division of A&G Pharma-
ceutical, Inc.) using their proprietary custom monoclonal
antibody development service. SJL/J mice (derived from
Swiss Webster) were immunized with recombinant full-
length wheat germ PfRH5 using Precision Antibody’s pro-
prietary protocol and adjuvant. Immunogenicity in mice
was assessed based on endpoint ELISA using recombinant
full-length wheat germ PfRH5 (100 ng/well). Once end-
point titers greater than 1:50,000 were reached, splenocytes
from the mouse with the highest titer were harvested for
fusion. Hybridomas were single-cell cloned and culture
supernatants tested for activity via ELISA using recombin-
ant full-length wheat germ PfRH5 (100 ng/well). Crudesupernatants from the highest responders were harvested
for testing in invasion inhibition assays. Supernatants
which inhibited parasite invasion by ≥60% were selected
for monoclonal purification.
Invasion inhibition assay (IIA)
Parasite culture maintenance and IIAs were performed as
described [20]. Purified IgG from naïve mouse sera was
used at equivalent concentrations as negative controls in
all IIAs. Crude supernatants from mouse hybridoma cul-
tures were tested at 1:5 dilutions. Purified monoclonal
antibodies were assayed at 0.025 to 0.1 mg/mL. Cardiac
bleed sera from the four animals immunized with the
5A08-VLP were pooled and the IgG fraction was purified
using Protein G Sepharose beads, dialyzed overnight in
1× PBS. Concentrations of IgG were determined against
a BSA standard curve on a spectrophotometer (BioRad)
and IIAs performed at 0.1 mg/mL to 1 mg/mL in 3D7.
All IIAs were done at least 2–3 times, in triplicate.
Immunofluorescence assay (IFA)
Mature schizont stage 3D7 parasites were smeared onto
slides and stored at −70°C before use. Slides were thawed
and fixed with 10% methanol/90% acetone for 20 min at
room temperature. After air-drying, the smears were
coated with anti-PfRH5 monoclonal antibody (1:20 in
1× PBS/1% BSA) and incubated at room temperature
for 1 h. Slides were washed by shaking in 1× PBS for
5 min then incubated with FITC-conjugated anti-mouse
antibody (1:50 in 1× PBS/1% BSA) for 1 h at room temp-
erature protected from light. All slides were washed by
shaking in 1x PBS for 5 min then mounted using 10 μg/mL
DAPI. Slides were observed under UV light. Supernatants
which recognized native PfRH5 antigen by IFA were
selected for monoclonal purification. Slides with mature
3D7 parasites were fixed and air dried as before and co-
stained with mouse anti-5A08-VLP (“Mα5A08-VLP”; 1:20)
and rabbit anti-PfRhop148 [25] (“RαPfRhop148”; 1:100) or
with mouse anti-5A08-VLP (“Mα5A08-VLP”; 1:20) and
anti-RhopH3 [25] (RαRhopH3; 1:500) in 1× PBS/1% BSA.
All slides were washed by shaking in 1× PBS for 5 min then
incubated with a mixture of FITC-conjugated anti-mouse
antibody (1:50) and TRITC-conjugated anti-rabbit IgG
(1:50) in 1× PBS/1% BSA) for 1 h at room temperature
protected from light. All slides were washed by shaking
in 1× PBS for 5 min.
Immunoblotting
Saponin-lysed pellets from mature-stage parasites, was
used to make a native protein lysate from mature 3D7
parasites. This was separated on 10% SDS-PAGE gels by
electrophoresis, transferred to nylon membrane. Immuno-
blotting of the membranes was performed using standard
techniques with purified monoclonal antibody at 1:2
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the primary antibodies. Mouse anti-HRP at 1:3,000 dilu-
tion was used the secondary antibody.
VLP libraries and affinity selection
Three rounds of affinity-selection were conducted by bio-
panning using an equal a mixture of four different random
sequence peptide libraries constructed by methods de-
scribed previously [26]. Each library displayed 6mer, 7mer,
8mer, or 10mer peptides, was constructed independently,
and contained about 1010 individual members.
5A08-VLP immunizations
The 5A08-VLP selectant was purified as described [27]
and three mice were immunized three times by intra-
muscular injection with 5 μg at two-week intervals in
the presence of the GLA-SE adjuvant. Two weeks after
the last immunization the animals were sacrificed and
their sera collected.
ELISA
The 5A08-VLP selectant was purified by chromatog-
raphy on Sepharose CL4B [27] and tested for its ability
to bind 2E11, 5A08, and 5A03 in direct ELISA. Purified
VLPs (500 ng) were adsorbed to a 96-well flat-bottomed
ELISA plate (Immulon 2) overnight at 4°C. Plates were
blocked with 5% (w/v) BSA in PBS for 2 h at 37°C and
then washed three times with 1x PBS. 1uL of sera was
diluted in 50 μL of PBS containing 2% BSA was added
to the plates and incubated for 1 h at 37°C. After three
washes with 1× PBS, an HRP-conjugated goat anti-mouse
IgG secondary antibody (Sigma, diluted 1:5,000) was
added and incubated for 1 h at 37°C. The plates were
washed again three times with 1x PBS, and the colori-
metric substrate, 2,2’-azino-bis(3-ethylbenzthiazoline-6-
sulphonic acid) (ABTS) was added and incubated at
room temperature until adequate color development
was obtained (about 15 min). Absorbance at 405 nm was
measured. All reactions were performed in duplicate.
Peptide ELISA was conducted by similar means, but
the synthetic peptide SAIKKPVTGGGC (500 ng) was
cross-linked through its C-terminal cysteine residue to
the amino groups of lysines on streptavidin coated wells
using the heterobifunctional cross-linker, succinimidyl
6-[(β-maleimidopropionamido)hexanoate] (SMPH). After
washing, the peptide was reacted with the serial dilutions
of sera for 2 h at room temperature. Reaction with sec-
ondary antibody and colorimetric assay were as described
above. In this case reactions were conducted in triplicate.
Results and discussion
Screening hybridoma supernatants
An ideal malaria vaccine antigen would be highly conserved
across a broad spectrum of Plasmodium falciparum strains,and would be essential to parasite viability and reproduc-
tion so resistance could not be easily acquired by mutation,
or by simply switching off expression. The merozoite
protein PfRH5 seems to meet these criteria, especially
as several attempts to delete the PfRH5 gene have been
unsuccessful, suggesting that PfRH5 is probably essential
to parasite viability [12,16,17]. To identify epitopes recog-
nized by invasion-inhibiting antibodies, we first identified
potent neutralizing monoclonal antibodies by screening
35 hybridoma supernatants from mice immunized with
full-length recombinant PfRH5 [20] for the ability to
inhibit invasion of erythrocytes by P. falciparum strain
3D7 in the invasion inhibition assay (IIA) and to recognize
native PfRH5 antigen by immunofluorescence (IFA).
Supernatants which showed inhibition ≥60% or were
positive by IFA were down selected for purification.
Of the eight purified monoclonal antibodies produced,
three inhibited 3D7 invasion by >95% at 0.1 mg/ml
(mAbs 2E11, 5A03 and 5A08; Figure 1A). The specificity
of these three mAbs towards native PfRH5 antigen was
confirmed by IFA and immunoblot analysis (Figures 1B
and C). There have been very few antibodies reported
to date that are able to inhibit invasion in vitro by such
a degree and this suggests that these mAbs target the
neutralizing epitope(s) of RH5.
Affinity selection of a peptide that binds the 5A08
antibody
To identify the epitope targeted specifically by the 5A08
mAb, (chosen as it completely inhibited invasion), affinity
selection using random sequence peptide libraries displayed
on virus-like particles of bacteriophage MS2 (MS2 VLPs)
with 5A08 as the selecting mAb (Figure 2) was performed.
The method is highly analogous to conventional phage
display, but is based on the VLPs that form when MS2
coat protein is expressed from a plasmid in Escherichia
coli. The ability to display libraries of diverse peptides
on the MS2 VLP and to then affinity select those rare
peptides that bind a target antibody depends on two
essential conditions: First, it is necessary to identify a
surface-exposed site in coat protein that tolerates pep-
tide insertions without disruption of protein folding or
VLP assembly. Coat protein’s AB-loop is prominently
exposed on the VLP surface, but in the wild-type protein
AB-loop insertions nearly always interfere with correct
folding. Fortunately, a simple means of conferring inser-
tion tolerance was found. Coat protein is a symmetric
dimer of identical polypeptide chains with the N-terminus
of one monomer lying in close physical proximity to the
C-terminus of the other. By duplicating the coat coding
sequence and fusing the two copies into a single reading
frame, a “single-chain dimer” that is dramatically more
stable thermodynamically, and highly tolerant of inser-
tions in one of its two AB-loops was created [27-29].
Figure 1 Purified anti-PfRH5 monoclonal antibodies inhibit invasion of P. falciparum strain 3D7. (A) The efficacy of purified anti-PfRH5
monoclonal antibodies (mAbs) to prevent invasion of 3D7 parasites was determined at 0.1 mg/mL. Three mAbs, 2E11, 5A03 and 5A08 were able to inhibit
invasion by 98%, 100% and 99%, respectively, while the inhibition of the remaining mAbs ranged from 20-45%. Error bars show standard error. (B)
Immunofluorescence assays show these three mAbs with high inhibition recognize native PfRH5 located at the apical end of merozoites. (C) Western
blot assay on mature 3D7 parasite lysate with these three purified mAbs also shows that native PfRH5 is recognized by each of these antibodies.
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type that forms the basis of all such technologies, the VLP
must encapsidate the nucleic acid that encodes coat
protein and its guest peptide. As it happens, the MS2
VLP efficiently encapsidates its own mRNA [27], meaning
that affinity selected sequences can be recovered and
amplified by reverse transcription and polymerase chain
reaction. Because of their multivalent presentation on the
VLP surface foreign peptides are highly immunogenic.
Therefore, the MS2 VLP can integrate the epitope iden-
tification and immunization functions into a single plat-
form and the cloned products of affinity selection can
be produced in bacteria, purified and then used directly
as vaccines.
The plasmid vectors and methods that facilitate the
construction of peptide libraries have been described
[26-28]. Random sequences of varying lengths are inserted
into one AB-loop of the single-chain dimer. When
expressed in bacteria the recombinant coat proteins self-
assemble into VLPs, each of which displays a different guest
peptide on its surface and encapsidates its own mRNA In
the present study, a mixture of random sequence 6-mer,
7-mer, 8-mer and 10-mer libraries, each comprised of
about 1010 independent clones were used [27]. Afterbio-panning on the 5A08 target, affinity-selected sequences
were recovered by reverse transcription of the coat protein-
specific mRNA they contained, followed by polymerase
chain reaction. The selected sequences were then re-cloned
to produce VLPs for additional rounds of selection. This
process normally requires several iterative selection rounds
to obtain a relatively simple population of peptides that
tightly bind the target antibody.
In this case, however, after only two rounds a virtually
homogeneous selectant population was obtained, in which
each of twelve individually characterized clones displayed
the peptide 8-mer, SAIKKPVT. A third round of affinity-
selection also identified the SAIKKPVT sequence in 7
of 8 clones, and the very similar 8-mer TAIKKVPT was
identified in one clone. Figure 3A shows the electrophor-
etic behaviour of the SAIKKPVT-containing particle at
the second round of selection compared to unmodified
MS2 VLPs. It is unlikely the selection passed through an
artificial bottleneck that restricted the diversity of the
selected sequence for reasons unrelated to its affinity for
the antibody as independent selections gave essentially
identical results, but at least one of the sequenced clones
shows a slight deviation for the major sequence, replacing
the serine at amino acid 1 with threonine. Also, selections
Figure 2 Library construction and affinity selection of MS2 VLPs. When expressed from a plasmid in bacteria, the coat protein of bacteriophage
MS2 forms a virus-like particle (VLP), which we have adapted for peptide display and affinity-selection. A complex library of random peptide sequences
is constructed at the level of plasmid DNA. When the DNA is expressed in E. coli, a library of corresponding VLPs is produced, as the recombinant coat
proteins self-assemble into VLPs, each of which displays a different guest peptide on its surface and encapsidates its own mRNA. These VLPs are
subjected to affinity selection with a specific mAb. Unbound VLPs are washed and discarded. VLPs which display a peptide with an affinity for
the mAb used are eluted, and subjected to RT-PCR to generate cDNA for another round of affinity selection. After affinity selection, the VLPs
were characterized to determine the sequence of the peptide.
Figure 3 Affinity selection using the anti-PfRH5 mAb 5A08 identifies a single, short linear epitope, AIKK. (A) Agarose gel of purified,
unmodified, MS2 VLP (left lane) and a single clone representative of the highly homogenous selectant population from twelve VLPs selected by
the anti-PfRH5-5A08 mAb (right lane), stained with ethidium bromide by virtue of the RNA within each VLP. (B) Characterization by sequencing
of clones from each round of affinity-selection showed each RH5-5A08 VLP displayed a four-amino acid sequence at its core, AIKK/R, and that by
round two, only VLPs with the AIKK epitope were selected for. The full length PfRH5 sequence (from PlasmoDB, gene ID PF3D7_0424100) contains
a 4-amino acid identity to the AIKK sequence that occurs only once near the PfRH5 N-terminus (amino acids 28–31, indicated with asterisks),
highlighting the potential importance of this epitope with binding to the RBC receptor during parasite invasion.
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mAbs, which effectively serve as positive controls for
the selection process as a whole, and at round 3 these
anti-HCV selections yielded diverse peptide families, all
of which show homology to their known epitopes (data
not shown), indicating that the selections functioned
normally.
The AIKK sequence contained within the peptide is
identical to one encountered near the PfRH5 N-terminus
(Figure 3B), suggesting this site represents the 5A08
epitope. It is believed that the N-terminal 21 amino
acids of PfRH5 contain a signal sequence that is proteo-
lytically removed from the mature protein [12,13,17].
Not only is AIKK the only sequence that survived two
selection rounds, but deep sequence analysis of the 200
most abundant first round selectants (from ~2,500) shows
that it is only one member of a much larger familyFigure 4 The anti-PfRH5 mAb 5A08 specifically recognizes the affinity
the 5A08-VLP, and a MCA-5792-VLP, show that the 5A08-VLP reacts with th
2E11 and 5A03, nor with MCA-5792 used here as a control, which reacts w
peptidoglycan; St8 is a VLP affinity-selected for its ability to interact with M
the synthetic SAIKKPVTGGGC peptide. ELISA assay shows the anti-peptide a
bearing the SAIKKPVTGGGC peptide. The synthetic peptide was bound to the
immunized mice show negligible anti-VLP peptide antibody titers in naïve anim
reaction with the peptide, but it was much lower and decreased quickly with d
and 3) showed high anti-VLP peptide antibody titers, two of the three giving sigsequence family whose common feature is the AIKK
(or AIKR) tetrapeptide, and the AIK(K/R) motif always
occupies amino acids 2–5 (from the N-end of the
sequences characterized. The fact that by round two of
affinity-selection SAIKKPVT was so clearly favored
over the other members of this family suggests that
amino acid residues outside the AIKK identity may serve
to most effectively present the core four-amino acid
epitope to the antibody in the context of the display site
on the MS2 coat protein AB-loop.
Surveys of gene polymorphism by deep sequence ana-
lysis of nearly 300 different African malaria samples show
the PfRH5 protein sequence is highly conserved [18,30]
and that none of the known polymorphisms affects the
AIKK epitope. The specific role of the AIKK epitope in
PfRH5 function is not known, but it is tempting to think
the epitope participates directly in interactions with the-selected VLP. (A) ELISA performed with different mAbs against with
e anti-PfRH5 5A08 mAb, but not with the two other anti-PfRH5 mAbs,
ell with its own selectant. MCA-5792 recognizes Staphylococcus aureus
CA-5792. (B) The 5A08-selected VLP elicits antibodies that recognize
ntibody titers of sera from mice immunized with the synthetic VLP
plates by chemical cross-linking. Pooled pre-immune sera from the
als. Pooled sera from mice immunized with MS2 itself also showed some
ilution. However, sera from all three mice immunized (indicated as 1, 2
nals well above background levels beyond the 1:5,120 dilution point.
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the 5A08 monoclonal antibody directly interferes with
binding. A recent report described neutralizing mAbs that
bind epitopes found in at least two defined regions of
the PfRH5 primary sequence [24]. Neither overlaps the
predicted 5A08 epitope. Interestingly the same report
found two classes of mAbs that had a severe inhibitory
effect on parasite invasion, yet only one group inhibited
PfRH5-Basigin binding [24].
Immunization with the 5A08 VLP selectant elicits
antibodies that recognize PfRH5 and strongly inhibit
parasite entry into erythrocytes
The purified 5A08 VLP selectant was tested by direct
ELISA for its ability to bind each of the three invasion-
inhibiting anti-PfRH5 mAbs (i.e. 5A08, 5A03, and 2E11).
As expected of an affinity-selectant, it bound significantly
only to the 5A08 antibody (Figure 4A). Three mice were
immunized with the VLP displaying the SAIKKPVT
sequence by intramuscular injection with 5 μg of VLP,
3 times at two-week intervals. To assess the relative
anti-peptide titers of the antisera, a synthetic peptide
representing the selected sequence was synthesized andFigure 5 The VLP bearing the SAIKKPVT peptide elicits antibodies tha
with the VLP displaying the SAIKKPVT peptide were tested for their ability to i
Invasion inhibition ranged from 22% to 92%. Purified IgG from naïve mouse s
show standard error. (B) Immunoblotting (left panel; expected size of native P
panel; apical end of merozoites are indicated by FITC staining) show the PfRHtested in ELISA for its ability to bind sera from the
immunized animals using sera serially diluted from 1:80
to 1:81,920 (Figure 4B). Unsurprisingly, the 5A08-VLPs
elicit antibodies that recognize a synthetic version of
the immunizing peptide. Most importantly, purified IgG
from the anti-5A08-VLP antiserum was potently inhibitory
in GIA, showing greater than 90% inhibition of parasite
entry at a concentration of 1 mg/mL IgG concentration
(Figure 5A). Remembering that only a small fraction of the
total IgG is likely to be specific for the 5A08 epitope, this
level of inhibition promises a significantly improved route
for eliciting anti-invasion antibodies. The reaction of the
antisera with native PfRH5 was confirmed by Western blot
analysis (Figure 5B), where it can be seen that sera against
5A08-VLP (lane 2) reacts with the same polypeptides as
seen by antibodies to the full-length RH5 (lane 1). Immu-
noblot analysis with negative control sera directed against
empty VLPs did not react with the 63 kDa PfRH5 band
(lane 3). IFA analysis was also performed to confirm
rhoptry localization of the target of the 5A08-VLP sera
(Figure 5C). Co-staining using anti-5A08-VLP sera along
with antibodies to known rhoptry markers, PfRhop148
(Figure 5C, top panel) and RhopH3 (Figure 5C, bottomt inhibit parasite invasion. (A) Pooled sera from mice immunized
nhibit 3D7 invasion (concentrations used from 0.1 mg/mL to 1.0 mg/mL).
era was used at equivalent concentrations as negative controls. Error bars
fRH5 at ~63 kDa indicated by arrow) and (C) immunofluorescence (right
5 specific VLP sera is able to recognize native PfRH5.
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of the 5A08-VLP. These studies thus indicated that the
5A08-VLP recognizes native PfRH5 in the rhoptries.
Several groups have shown that the intact PfRH5
protein, whether administered as a recombinant protein
or expressed from viral vectors, elicits antibodies that
inhibit parasite entry into erythrocytes in vitro [18,19,21].
But subunit vaccines generally elicit strong responses
only after several administrations, and the immunity they
engender is frequently relatively short-lived [31]. This is
probably because the survival potential of a plasma cell
and its level of antibody production are determined during
its initial interaction with antigen. Recombinant proteins,
and other antigens that lack multivalency, do not strongly
activate B cell activation through BCR crosslinking
[32,33]. Because of their multivalency, on the other hand,
VLPs present peptide epitopes as potent immunogens that
elicit strong and durable antibody responses, often after
only a single administration [34]. In addition to its high
immunogenicity, the MS2 VLP has the ability to identify
epitopes by affinity-selection. Given a mAb with neutraliz-
ing activity, the work presented here shows that the MS2
VLP can provide a direct route to an epitope-specific
vaccine candidate.
Conclusions
These results add to other studies that point to the poten-
tial of PfRH5 as a vaccine antigen [18-24,35], although
none of the antibodies reported so far has approached the
high level of invasion inhibition shown by our three
mAbs, 2E11, 5A03 and 5A08, or the sera that were raised
against the VLP that displays the 5A08 epitope. This
highlights the relative importance of the AIKK epitope
for effective parasite neutralization. Further, the work
presented here shows that when displayed on the MS2
VLP even a single PfRH5 epitope can elicit antibodies that
potently inhibit erythrocyte invasion by parasites. The
high immunogenicity of peptides displayed multivalently
on MS2 VLPs permits the use of the affinity-selected VLP
itself as a vaccine immunogen. Thus the VLP integrates
the epitope discovery and immunization functions into a
single platform. While the PfRH5 protein itself might
form the basis of an effective subunit vaccine, an epitope-
specific vaccine based on the MS2 VLP platform has some
advantages. Clinical trials conducted with VLP-based bio-
logics have demonstrated that these products have good
safety profiles [36-39]. Even at low doses VLPs elicit high-
titer and remarkably durable antibody responses, poten-
tially obviating the need for adjuvants [40]. Furthermore,
because MS2 VLPs are produced at high levels in bacteria
they should be relatively easy and cheap to manufacture,
and the particle itself is relatively stable. These features
are particularly important in the developing world, where
the burden of malaria is the highest.Competing interests
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